Abstract
Altered expression of CCN3 has been observed in a variety of musculoskeletal tumours, including Ewing's sarcoma (ES). Despite its widespread distribution, very little is known about its biological functions and molecular mechanisms of action. We transfected CCN3 gene into a CCN3-negative ES cell line and analysed the in vitro and in vivo behaviours of stably transfected clones. Forced expression of CCN3 significantly reduced cell proliferation in vitro, growth in anchorage-independent conditions and tumorigenicity in nude mice. Despite the antiproliferative effect, CCN3-transfected ES cells displayed increased migration and invasion of Matrigel. The decreased expression of α2β1 integrin receptor and the increased amount of cell surface-associated matrix metalloproteinase (MMP)-9 following the expression of CCN3 may be the basis for the increased migratory abilities of transfected cells. Cells lacking α2β1 are less facilitated to have stable anchorage since the predominant collagen extracted from ES tissue is indeed type I collagen and proMMP-9 was recently found to provide a cellular switch between stationary and migratory ES cell phase. Our findings are in line with those recently obtained in glioblastoma. However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- NOV :
-
nephroblastoma overexpressed gene
- Cyr61:
-
cystein-rich protein 61
- CTGF:
-
connective tissue growth factor
- PDGF:
-
platelet-derived growth factor
- ECM:
-
extracellular matrix
- ES:
-
Ewing's sarcoma
- MMP:
-
metalloprotease
- PDGFR:
-
platelet-derived growth factor receptor
- MAPK:
-
mitogen-activated protein kinase
- IGF:
-
insulin-like growth factor
- IGF-IR:
-
insulin-like growth factor receptor I
- MAb:
-
monoclonal antibody
- IMDM:
-
Iscove's modified Dulbecco's medium
- FBS:
-
fetal bovine serum
- RT–PCR:
-
reverse transcription polymerase chain reaction
References
Aaronson TA and Todaro GJ . (1968). Science, 162, 1024–1026.
Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D and Picci P . (2000). J. Clin. Oncol., 18, 4–11.
Bork P . (1993). FEBS Lett., 327, 125–130.
Brigstock DR . (1999). Endocr. Rev., 20, 189–206.
Brigstock DR . (2003). J. Endocrinol., 178, 169–175.
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA . (1996). Cell, 85, 683–693.
Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN and Perbal B . (1998). Am. J. Pathol., 152, 1563–1574.
de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH and Ladanyi M . (2000). Cancer, 89, 783–792.
de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG and Ladanyi M . (1998). J. Clin. Oncol., 6, 1248–1255.
Egeblad M and Werb Z . (2002). Nat. Rev. Cancer, 2, 161–174.
Ellis PD, Chen Q, Barker PJ, Metcalfe JC and Kemp PR . (2000). Arteriosc. Thromb. Vasc. Biol., 20, 1912–1919.
Fan W-H and Karnovsky MJ . (2002). J. Biol. Chem., 277, 9800–9805.
Fridman R, Toth M, Chvyrkova I, Meroueh SO and Mobashery S . (2003). Cancer Metastasis Rev., 22, 153–166.
Glukhova L, Angevin E, Lavialle C, Cadot B, Terrier-Lacombe MJ, Perbal B, Bernheim A and Goguel AF . (2001). Cancer Genet. Cytogenet., 130, 105–110.
Gupta N, Wang H, McLeod TL, Naus CC, Kyurkchiev S, Advani S, Yu J, Perbal B and Weichselbaum RR . (2001). Mol. Pathol., 54, 293–299.
Harvey W, Squier V, Duance VC and Pritchard J . (1982). Br. J. Cancer, 46, 848–855.
Hattinger CM, Potschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, Kager L, Thorner P, Knuutila S, Niggli FK, Ambros PF, Gadner H and Betts DR . (2002). Br. J. Cancer, 86, 1763–1769.
Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J and Perbal B . (1992). Mol. Cell. Biol., 12, 10–21.
Lake AC and Castellot Jr JJ . (2003). Cell. Commun. Signal., 1, 5–18.
Lau LF and Lam SCT . (1999). Exp. Cell. Res., 248, 44–57.
Laurent M, Martinerie C, Thibout H, Hoffman MP, Verrecchia F, Le Bouc Y, Mauviel A and Kleinman HK . (2003). FASEB J., 17, 1919–1921.
Lin CG, Leu S-J, Chen N, Tebeau CM, Lin S-X, Yeung C-Y and Lau LF . (2003). J. Biol. Chem., 278, 24200–24208.
Liu C, Liu X-J, Crowe PD, Kelner GS, Fan J, Barry G, Manu F, Ling N, De Souza EB and Maki RA . (1999). Gene, 238, 471–478.
Lopez-Guerrero JA, Pellin A, Noguera R, Carda C and Llombart-Bosch A . (2001). Lab. Invest., 81, 803–814.
Maillard M, Cadot B, Ball RY, Sethia K, Edwards D, Perbal B and Tatoud R . (2001). Mol. Pathol., 54, 275–280.
Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi P, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P and Scotlandi K . (2002). Am. J. Pathol., 160, 849–859.
Ohali A, Avigad S, Cohen IJ, Meller I, Kollender Y, Issakov J, Gelernter I, Goshen Y, Yaniv I and Zaizov R . (2003). J. Clin. Oncol., 21, 3836–3843.
Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, Hoffmann C, Hillmann A, Wai D, Schaefer KL, Boecker W, Juergens H, Winkelmann W and Dockhorn-Dworniczak B . (2001). Genes Chromosomes Cancer, 32, 164–171.
Perbal B . (1988). Practical Guide to Molecular Cloning. Wiley and Sons: New York.
Perbal B . (2001). Mol. Pathol., 54, 57–79.
Perbal B . (2004). Lancet, 36, 62–64.
Perbal B, Martinerie C, Sainson R, Werner M, He B and Roizman B . (1999). Proc. Natl. Acad. Sci. USA, 96, 869–874.
Perri T, Fogel M, Mor S, Horev G, Meller I, Loven D, Issakov J, Kollender Y, Smirnov A, Zaizov R and Cohen I J . (2001). Pediatr. Hematol. Oncol., 18, 325–334.
Planque N and Perbal B . (2003). Cancer Cell Int., 3, 1–15.
Sanceau J, Truchet S and Bauvois B . (2003). J. Biol. Chem., 278, 36537–36546 (Epub 2003 July 07).
Scholz G, Martinerie C, Perbal B and Hanafusa H . (1996). Mol. Cell. Biol., 16, 481–486.
Scotlandi K, Benini S, Manara MC, Serra M, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Chano T, Picci P and Baldini N . (2000). J. Orthop. Res., 18, 959–966.
Soon LL, Yie TA, Shvarts A, Levine AJ, Su F and Tchou-Wong KM . (2003). J. Biol. Chem., 278, 11465–11470 (Epub 2003 January 15).
Stein GS, Lian JB and Owen TA . (1990). FASEB J., 4, 3111–3123.
vanValen F, Hanenberg H and Jurgens H . (1994). Eur. J. Cancer, 30A, 2119–2125.
Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH and Ladanyi M . (2000). Cancer, 89, 793–799.
Yabe H, Fukuma M, Urano F, Yoshida K, Kato S, Toyama Y, Hata J and Umezawa A . (2002). Biochem. Biophys. Res. Commun., 293, 61–71.
Yu C, Le A-T, Yerger H, Perbal B and Alman BA . (2003). J. Pathol., 201, 609–615.
Yu Q and Stamenkovic I . (1999). Genes Dev., 13, 35–48.
Zielenska M, Zhang ZM, Ng K, Marrano P, Bayani J, Ramirez OC, Sorensen P, Thorner P, Greenberg M and Squire JA . (2001). Cancer, 91, 2156–2164.
Acknowledgements
This work was supported by grants from the Italian Association for Cancer Research and the Italian Ministry of Health. Experiments performed in the laboratory of B Perbal were funded by Association pour la Recherche contre le Cancer (ARC), Ligue Nationale contre le Cancer (Comités du Cher et de l'Indre) and Ministère de l'Education Nationale et de la Recherche. SB performed constructions of the vectors in the laboratory of B Perbal when she was supported by a UICC International Cancer Technology Transfer Fellowship (ICRETT). We thank Professor Bernard Roizman (University of Chicago) who provided facilities and support B Perbal for the initial construction of pCMV derivatives and Professor Stanimir Kyurkchiev for CCN3 purification.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benini, S., Perbal, B., Zambelli, D. et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24, 4349–4361 (2005). https://doi.org/10.1038/sj.onc.1208620
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208620
Keywords
This article is cited by
-
CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer
Cell Death & Disease (2023)
-
Time has come to address the spatiotemporal combinatorial model for CCN proteins biological activitites by spatial transcriptomics and genome wide association studies
Journal of Cell Communication and Signaling (2023)
-
The role of CCNs in controlling cellular communication in the tumor microenvironment
Journal of Cell Communication and Signaling (2023)
-
Do not overwork: cellular communication network factor 3 for life in cartilage
Journal of Cell Communication and Signaling (2023)
-
Nephroblastoma overexpressed protein (NOV) enhances 5-Fu-mediated inhibitory effect of colorectal cancer cell proliferation via JNK/AP-1/caspase-8/caspase-3 pathway
Discover Oncology (2021)